A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF PF-08642534 IN HEALTHY ADULT PARTICIPANTS

The purpose of this study is to learn if a medicine called itraconazole changes how the body processes the study medicine (PF-08642534) in healthy adults.

This study is seeking healthy participants (men or women) who:

• are aged 18 to 65 years of age
• are confirmed to be healthy by their medical history and medical tests
• have body mass index (BMI) of 16 to 30 kilograms per meter squared
• have a total body weight of more than 50 kilograms.

Participants will receive single doses of the study medicine (PF-08642534) with and without itraconazole.

The total planned time of participation is about 12 weeks. The study consists of:

• a screening period of up to 28 days before taking study drug
• about 4 weeks of staying in the study clinic
• a follow-up contact that will occur 28 to 35 days after taking itraconazole the last time.

Inclusion criteria:

• Generally healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, blood pressure, pulse rate and standard 12-lead electrocardiogram (ECG).
• Body Mass Index (BMI) of 16-30 kilograms per meter squared, inclusive, and a total body weight greater than 50 kilograms (110 pounds).

Exclusion criteria:

• Evidence or history of clinically significant disease
• Specified abnormalities in safety assessments at Screening